Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVANZ Phleum pratense maintenance dose
2011-000120-15Phase 2Completed
- Sponsor
- ALK-Abelló
- Start
- Jun 2011
- Countries
- 1
01
Overview
Phase 2, randomised trial of phleum pratense allergen extract in allergic rhinoconjunctivitis (ARC) and asthma (3 arms), sponsored by ALK-Abelló. Primary endpoint: Combined rhinoconjunctivitis daily symptom score and daily medication score over the entire grass pollen season. Started Jun 2011; status: completed.
02
Drugs
phleum pratense allergen extract
03
Conditions
allergic rhinoconjunctivitis (ARC)asthma
Beyond the preview
Go deeper on 2011-000120-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000120-15.